In the September 11 Proceedings of the National Academy of Sciences, Therese Sørlie and colleagues at the The Norwegian Radium Hospital, Oslo, Norway, show how cDNA microarray data may be used to define subclasses of breast carcinomas and to predict clinical outcome (Proc Natl Acad Sci USA 2001, 98:10869-10874).

They analysed 78 breast cancer samples (mostly ductal carcinomas) and compared the expression profiles of 456 genes with profiles from normal breast tissue. They then classified the cancers into epithelium-like, ERBB2-overexpressing and normal-breast-like groups, and used different profiling patterns to sub-divide the estrogen-receptor-positive group into two distinct subgroups.

Sørlie et al. found that the microarray-defined subgroups of patients had different clinical outcomes, suggesting the power of microarray-based studies for determining prognoses.

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?